Entrada Therapeutics, Inc.
TRDA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.71 | -0.01 | 0.00 | -1.45 |
| FCF Yield | -11.70% | -10.71% | -10.68% | -4.57% |
| EV / EBITDA | -4.24 | -5.68 | -17.29 | -136.24 |
| Quality | ||||
| ROIC | -12.15% | -10.83% | -4.59% | 1.82% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 97.35% |
| Cash Conversion Ratio | 0.64 | 0.68 | 2.22 | -27.94 |
| Growth | ||||
| Revenue 3-Year CAGR | -10.97% | 22.32% | 89.62% | 5,951,190.82% |
| Free Cash Flow Growth | 5.45% | 24.94% | -22.99% | -29.45% |
| Safety | ||||
| Net Debt / EBITDA | 0.87 | 0.39 | 0.52 | 8.62 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 54.46 | 8.95 | 8.86 |